Our study is the first to show that the use of β-blockers was associated with a reduction in MMP-2 level, TIMP-2 level, and the MMP-2/TIMP-2 ratio in patients with CKD on conservative treatment. The gene discussed is MMP2; the disease is chronic kidney disease.